Thrombotic complications in patients treated with immune checkpoint inhibitors: a retrospective study of incidence, risk factors, and survival outcomes.

Authors

Ali Awada, Ali Ghais, Sary Faraj, Ali Tarhini, Joe Rizkallah, Nour Mashmoushi, Souad Susan Sawaf, Nicole Charbel, Jana Haroun, Akel Khaled, Mikel Madi, Katia Kteich, Sara El Mustapha, Mohammad Hassan, Firas Kreidieh

Published in

Frontiers in immunology. Volume 17. Pages 1852772. Epub Aug 14, 2026.

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer outcomes across multiple malignancies. However, emerging evidence suggests that thrombotic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE) are serious complications that may negatively affect survival. This study aims to determine their incidence, identify independent risk factors, and evaluate effects on outcomes and survival.
We retrospectively reviewed adult patients treated with ICIs at a tertiary academic center. Thrombotic events were classified as VTE or ATE occurring from ICI initiation through follow-up. Clinical, laboratory, and treatment-related variables were collected. Kaplan-Meier methods and multivariable Cox proportional hazards models were used to evaluate survival impact and identify independent predictors.
Among 750 patients treated with ICIs, 125 (16.6%) thrombotic events occurred over a median follow-up of 25 months. Of these events, 105 (84.0%) were VTE and 20 (16.0%) were ATE. Of all thrombotic events, 38% occurred within the first 6 months, 56% within 12 months, 67% within 18 months, and 74% within 24 months. Independent predictors of TE included prior VTE (HR 1.84, 95% CI 1.12-3.01; p = 0.015), lower baseline hemoglobin (HR 0.88, 95% CI 0.80-0.99; p = 0.036), and older age at immunotherapy initiation (HR 1.07 per year increase, 95% CI 1.04-1.11; p < 0.001).Thrombotic events were associated with significantly worse overall survival (OS) (log-rank p < 0.001) and remained independently associated with mortality in multivariable analysis (HR 2.55, 95% CI 1.89-3.43; p < 0.001). Additionally, prior thrombotic events (HR 1.86, 95% CI 1.29-2.69; p = 0.001) and a Khorana score ≥2 (HR 1.31, 95% CI 1.13-1.50, p<0.001) were independently associated with worse OS.
Thrombotic events are common in patients receiving ICIs and are independently associated with worse survival. Risk-based and personalized assessment of thrombotic events can help guide monitoring and management strategies.

PMID:
42666283
Bibliographic data and abstract were imported from PubMed on 29 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.